乳腺癌体内分离EpCAM阳性循环肿瘤细胞的综合分子分析
本研究对42例早期和23例转移性乳腺癌患者的体内分离CTC进行基因表达、DNA突变和DNA甲基化分析,并以19例健康供体为对照。结果显示基于肌酸激酶筛选的综合分子分析较CellSearch或免疫荧光染色更敏感,支持其作为液体活检分子诊断工具。
要点
- 体内分离CTC的综合分子分析在乳腺癌中可行,可同步检测基因表达、突变与甲基化。
- 基于肌酸激酶筛选的综合分子分析灵敏度高于CellSearch或免疫荧光染色。
- 早期和转移性乳腺癌患者CTC中可检出PIK3CA突变与ESR1甲基化。
核心结论
- 体内CTC分离结合基因表达、DNA突变和DNA甲基化水平的综合分子分析是乳腺癌液体活检分子诊断的有力方法。
研究设计与样本
- 前瞻性收集42例早期和23例转移性乳腺癌患者的体内分离CTC,并以19例健康供体为对照,在治疗前后分析基因表达、DNA突变和DNA甲基化。
主要发现
- 健康供体CK8、CK18、CK19、ERBB2、TWIST1、VEGF、ESR1、PR和EGFR表达均为阴性。
- 早期乳腺癌治疗前和治疗后分别有23/42(54.8%)和8/13(61.5%)CTC表达至少一种基因,转移性乳腺癌分别为20/23(87.0%)和5/7(71.4%)。
- 早期乳腺癌治疗前后分别有11/42(26.2%)和3/13(23.1%)CTC检出PIK3CA突变,转移性乳腺癌分别为11/23(47.8%)和2/7(28.6%)。
- 早期乳腺癌治疗前后分别有5/32(15.7%)和1/10(10.0%)CTC检出ESR1甲基化,转移性乳腺癌一线治疗前为3/15(20.0%)。
临床怎么用
- 对乳腺癌患者可考虑体内分离CTC并行基因表达、突变和甲基化综合分子分析以辅助液体活检分子诊断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circulating tumor cell (CTC) analysis is highly promising for liquid biopsy-based molecular diagnostics. We undertook a comprehensive molecular analysis of in vivo isolated CTCs in breast cancer (BrCa). METHODS: In vivo isolated CTCs from 42 patients with early and 23 patients with metastatic breast cancer (MBC) were prospectively collected and analyzed for gene expression, DNA mutations, and DNA methylation before and after treatment. 19 healthy donor (HD) samples were analyzed as a control group. In identical blood draws, CTCs were enumerated using CellSearch® and characterized by direct IF staining. RESULTS: All 19 HD samples were negative for CK8, CK18, CK19, ERBB2, TWIST1, VEGF, ESR1, PR, and EGFR expression, while CD44, CD24, ALDH1, VIM, and CDH2 expression was normalized to B2M (reference gene). At least one gene was expressed in 23/42 (54.8%) and 8/13 (61.5%) CTCs in early BrCa before and after therapy, and in 20/23 (87.0%) and 5/7 (71.4%) MBC before and after the first cycle of therapy. PIK3CA mutations were detected in 11/42 (26.2%) and 3/13 (23.1%) in vivo isolated CTCs in early BrCa before and after therapy, and in 11/23 (47.8%) and 2/7 (28.6%) MBC, respectively. ESR1 methylation was detected in 5/32 (15.7%) and 1/10 (10.0%) CTCs in early BrCa before and after therapy, and in 3/15(20.0%) MBC before the first line of therapy. The comprehensive molecular analysis of CTC revealed a higher sensitivity in relation to CellSearch or IF staining when based on creatine kinase selection. CONCLUSIONS: In vivo-CTC isolation in combination with a comprehensive molecular analysis at the gene expression, DNA mutation, and DNA methylation level comprises a highly powerful approach for molecular diagnostic applications using CTCs.
引用
- Strati A, Zavridou M, Kallergi G, et al. A Comprehensive Molecular Analysis of in Vivo Isolated EpCAM-Positive Circulating Tumor Cells in Breast Cancer. Clin Chem. 2021. PMID: 34322698. doi:10.1093/clinchem/hvab099
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。